Saira Babar, MD
Family Medicine · Jefferson City, MONPI 1306822317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 468 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$1K
- Novo Nordisk$838
- Amgen$623
- Lilly USA, LLC$346
- Astellas Pharma US Inc$265
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,728100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 112 | $1,260 |
| AbbVie(2 entities) | 65 | $1,175 |
| Novo Nordisk | 69 | $838 |
| Amgen | 43 | $623 |
| Lilly USA, LLC | 23 | $346 |
| Astellas Pharma US Inc | 12 | $265 |
| AstraZeneca | 17 | $259 |
| Boehringer Ingelheim | 14 | $230 |
| GSK | 16 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $180 |
| Dexcom, Inc. | 7 | $169 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $130 |
| Teva Pharmaceuticals USA, Inc. | 7 | $111 |
| Phathom Pharmaceuticals, Inc. | 6 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Exact Sciences | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Johnson & Johnson | 4 | $57 |
| Abbott | 3 | $51 |
| Bayer | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Vertex | 2 | $44 |
| Novartis | 3 | $43 |
| Medtronic | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| Corium, LLC | 2 | $28 |
| Biogen | 2 | $27 |
| Amarin Pharma, Inc. | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Edwards Lifesciences | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$6,736 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $132,779 |
| JanuviaSitagliptin Phosphate | 95 | $87,804 |
| JardianceEmpagliflozin | 80 | $84,499 |
| EliquisApixaban | 94 | $78,493 |
| MounjaroTirzepatide | 33 | $65,938 |
| TrulicityDulaglutide | 36 | $48,959 |
| XareltoRivaroxaban | 23 | $30,276 |
| ProliaDenosumab | 13 | $20,221 |
| FarxigaDapagliflozin Propanediol | 15 | $15,429 |
| CreonLipase/Protease/Amylase | 12 | $14,758 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $14,407 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,989 |
| MyrbetriqMirabegron | 20 | $10,787 |
| LinzessLinaclotide | 18 | $9,976 |
| Levothyroxine Sodium | 729 | $8,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $838 | $132,779106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $346 | $114,89769 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $230 | $90,20292 claims |
| PfizerEliquis, Abrysvo | $1,260 | $82,399107 claims |
| Johnson & JohnsonXarelto | $57 | $30,27623 claims |
| AstraZenecaFarxiga, Symbicort | $259 | $29,83758 claims |
| AbbVieCreon, Linzess, Synthroid | $1,175 | $27,13692 claims |
| AmgenProlia | $623 | $20,22113 claims |
| GSKTrelegy Ellipta, Arexvy | $228 | $16,75134 claims |
| Astellas Pharma US IncMyrbetriq | $265 | $10,78720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Jefferson City
- George CarrJefferson City$25K
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.